Prognostic factors of intraperitoneal chemotherapy for peritoneal carcinomatosis of gastric cancer: A retrospective study from a single center.
Peritoneal carcinomatosis (PC) of gastric origin is currently recognized as a terminal disease with a poor prognosis. Advancements in novel therapeutic approaches, including intraperitoneal chemotherapy (IPC), have recently been made and it is believed that this may have contributed to the improved survival observed in patients with PC. The present study aimed to investigate overall survival (OS) and the associated prognostic factors in patients with PC of gastric origin who underwent IPC. A total of 57 patients were studied, with a median age of 51 years. The median follow-up time was 12.4 months. PC was diagnosed in all patients with gastric cancer. The median survival time of all patients was 10.1 months, whilst the OS rate at 1, 2 and 3 years was observed to be 46, 19 and 12%, respectively. Symptomatic ascites and a signet ring cell (SRC) histopathological type were demonstrated to signify a poor prognosis. Complete resection of all gross disease (CCR-0) and an increased number of cycles of systemic chemotherapy were independent factors that were observed to correlate with increased OS. The most common morbidities of grade 3/4 adverse effects were bone marrow suppression, nausea or vomiting, and diarrhea. In conclusion, IPC is an important treatment option for patients with PC that has originated from gastric cancer. Symptomatic ascites and SRC adenocarcinoma serve as negative clinicopathological prognostic factors, whilst CCR-0 and increased systemic chemotherapy cycles (≥4 cycles) may prove to be an important therapeutic option for PC patients.
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China; Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Yuanjiagang, Yuzhong 400016, P.R. China.
Hai-Tao
HT
Men
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Hong-Feng
HF
Gou
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Ji-Yan
JY
Liu
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Qiu
Q
Li
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
DE-Yun
DY
Luo
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Feng
F
Bi
Division of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, P.R. China.
Meng
M
Qiu
cytoreductive surgery; gastric cancer; intraperitoneal chemotherapy; peritoneal carcinomatosis